Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263921 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
A Phase 1 study of Bioavailability, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05263921: Completed Phase 1 study of Bioavailability, sponsored by Pfizer.
NCT05263921 is a Phase 1 study of Bioavailability that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 37-participant average among 8 other Bioavailability trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05263921, a Phase 1 study of Bioavailability, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailability of the PF-07321332/ritonavir oral powder formulation as well as the safety, tolerability, and palatability of PF-07321332/ritonavir oral powder in healthy adult participants.
Primary Outcome
Area under the plasma concentration time profile from time 0 extrapolated to infinity (AUCinf) was measured. AUCinf was determined by AUClast + (Clast/kel), where Clast is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis.
Conditions Studied
Interventions
- DRUG PF-07321332/ritonavir
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 1 |
What the finished NCT05263921 record still lists
NCT05263921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 37-participant average among 8 other Bioavailability trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Bioavailability appearing as the primary indexed condition, and to 1 intervention - of which PF-07321332/ritonavir is the first listed.
NCT05263921 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05263921 about?
NCT05263921 is a clinical study titled "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants". The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailab...
What is the current status of trial NCT05263921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-03-10. Estimated completion is 2022-05-19.
What conditions does trial NCT05263921 study?
This clinical trial studies the following conditions: Bioavailability.
What interventions are being tested in trial NCT05263921?
The interventions under investigation include: PF-07321332/ritonavir (DRUG).
Who is sponsoring clinical trial NCT05263921?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263921 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioavailability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05263921's enrollment target sits among peer trials
12 8th of 8 the lowest of 8 other Bioavailability trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bioavailability trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
COMPLETED · Phase 1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
COMPLETED · Phase 1
-
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI